Inflammation Pharmacological Reaction and YMDD Mutational Patterns in Lamivudine Therapeutics Hepatitis B Virus

Background/Aims : Emergence of tyrosine-methionine-aspartate-aspartate (YMDD) motif in reverse transcriptase is a serious problem chronic hepatitis B(CHB) patients after Lamivudine (LAM) therapy. However, the relationship between inflammation pharmacological reaction and YMDD mutational patterns CHB has not been well-characterized. The aim this study was to investigate different mutants patients. Methods We investigated through biochemical, serological virological detection among 83 patients, including 25 mutants, under detection, 33 control without mutants. Results Prevalence mutation different. Among YIDD dominant (72%), followed YVDD (16%) hybrid + (12%). time course during mutations also 52.4% developed less than 12 months LAM Serum B virus (HBV) DNA level with were significantly higher that negative groups. HbsAg HbeAg those groups, despite no significant difference found forserum HbeAb. ALT AST levels group. Conclusions Illuminating pathological process may have implications for future therapy This impact on choice treatment strategies lamivudine-resistant HBV.